Inhibitors of EZH2 have shown potential in reducing tumor growth and enhancing the efficacy of immune checkpoint inhibitors (ICIs) like anti-PD-1/PD-L1 antibodies in various cancers [23]. This evidence concerns the gene EZH2 and neoplasm.